Page 5 - Barry Ticho News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Barry ticho. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Barry Ticho Today - Breaking & Trending Today

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $14.00 at Cantor Fitzgerald

Stoke Therapeutics (NASDAQ:STOK – Free Report) had its target price decreased by Cantor Fitzgerald from $18.00 to $14.00 in a research note released on Tuesday morning, Marketbeat.com reports. Cantor Fitzgerald currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2023 earnings at ($2.42) EPS and FY2024 earnings at […] ....

United States , Barry Ticho , Jonathan Allan , Stoke Therapeutics Inc , Metlife Investment Management , Needham Company , Stoke Therapeutics Company Profile , Canaccord Genuity Group , Cantor Fitzgerald , Securities Exchange Commission , York Mellon Corp , Jpmorgan Chase Co , Swiss National Bank , Stoke Therapeutics , Free Report , Stoke Therapeutic , Genuity Group , Moderate Buy , Get Free Report , General Counsel Jonathan Allan , Exchange Commission , National Bank , New York Mellon Corp , Life Investment Management , Rhumbline Advisers , Stoke Therapeutics Daily ,

HC Wainwright Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK)

HC Wainwright reiterated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $35.00 price target on the stock. HC Wainwright also issued estimates for Stoke Therapeutics’ Q3 2023 earnings at ($0.63) EPS, FY2023 earnings at ($2.56) EPS, FY2024 earnings at […] ....

United States , Jonathan Allan , Barry Ticho , Stoke Therapeutics Inc , Charles Schwab Investment Management Inc , Citigroup Inc , Metlife Investment Management , Cantor Fitzgerald , Canaccord Genuity Group , Needham Company , Dimensional Fund Advisors , Securities Exchange Commission , Stoke Therapeutics Company Profile , Mirae Asset Global Investments Co , Stoke Therapeutics , Free Report , Moderate Buy , Get Free Report , General Counsel Jonathan Allan , Exchange Commission , Life Investment Management , Asset Global Investments , Schwab Investment Management , Fund Advisors , Stoke Therapeutics Daily ,

Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a report issued on Tuesday, Benzinga reports. The firm currently has a $35.00 price target on the stock. HC Wainwright also issued estimates for Stoke Therapeutics’ Q3 2023 earnings at ($0.63) EPS, FY2023 earnings at ($2.56) EPS, FY2024 earnings […] ....

United States , Hong Kong , Jonathan Allan , Barry Ticho , Securities Exchange Commission , Cantor Fitzgerald , Ensign Peak Advisors Inc , Stoke Therapeutics Inc , Needham Company , Canaccord Genuity Group , Great West Life Assurance Co , Hong Kong Ltd , Stoke Therapeutics , Free Report , Moderate Buy , Get Free Report , General Counsel Jonathan Allan , Exchange Commission , Peak Advisors Inc , Kong Ltd , West Life Assurance , Quantbot Technologies , Stoke Therapeutics Daily ,

Stoke Therapeutics (NASDAQ:STOK) Earns Outperform Rating from Credit Suisse Group

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at Credit Suisse Group in a research report issued on Tuesday, Benzinga reports. They presently have a $23.00 target price on the stock. Credit Suisse Group’s price objective would indicate a potential upside of 294.51% from the company’s current […] ....

United States , New Zealand General , New Zealand , Barry Ticho , Jonathan Allan , Securities Exchange Commission , Cantor Fitzgerald , Canaccord Genuity Group , Needham Company , Millennium Management , Credit Suisse Group , Wellington Management Group , Stoke Therapeutics Inc , Stoke Therapeutics , Get Free Report , Suisse Group , Genuity Group , Therapeutics Trading Down , Exchange Commission , General Counsel Jonathan Allan , Management Group , Stoke Therapeutics Daily , Nasdaq Stok , Reiterated Rating , Credit Suisse Group Ag ,

Stoke Therapeutics (NASDAQ:STOK) Releases Earnings Results, Misses Expectations By $0.06 EPS

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.06), MarketWatch Earnings reports. Stoke Therapeutics had a negative net margin of 679.83% and a negative return on equity of 47.86%. Stoke Therapeutics Stock […] ....

United States , Barry Ticho , Jonathan Allan , Stoke Therapeutics Inc , Credit Suisse Group , York Mellon Corp , Swiss National Bank , Jpmorgan Chase Co , Needham Company , Metlife Investment Management , Stoke Therapeutics , Get Free Report , Marketwatch Earnings , General Counsel Jonathan Allan , National Bank , New York Mellon Corp , Life Investment Management , Rhumbline Advisers , Suisse Group , Stoke Therapeutics Daily , Nasdaq Stok ,